Jarushka Naidoo: The largest study evaluating association between specific irAEs and IO outcomes
Jarushka Naidoo, Thoracic Oncologist at the Beaumont Hospital Dublin, shared a post on X about a recent paper by her and colleagues published in Journal for ImmunoTherapy of Cancer:
“Pleased to publish the largest study evaluating association between specific Immune-related adverse events and IO outcomes on Journal for ImmunoTherapy of Cancer:
- 9521 patients in 14 atezolizumab mono/combo trials
- G1-2 skin Immune-related adverse events, thyroid, pneumonitis associated OS p<0.05
- G3-4 pneumonitis, colitis associated OS p<0.01
Congrats to all authors on this massive effort across NSCLC, kidney cancer, urothelial cancer, TNBC and more, and in particular to first author Gonzalo Duran-Pacheco. A great contribution to the irAE literature.”
“Correlation of safety and efficacy of atezolizumab therapy across indications”
Authors: Gonzalo Durán-Pacheco, Scott Chandler, Vidya Maiya, Rajat Mohindra, Jarushka Naidoo et al.
More posts featuring Jarushka Naidoo.
Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland.
She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.
She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023